Search
Powered By HealthLine
Special Offers
Health Tools
 Mammogram Guide
 Check A Breast Cancer Symptom
 Understanding Skin Cancer
 Skin Cancer Q&A
 Prostate Cancer Treatment
Featured Conditions
 Breast Cancer
 Skin Cancer
 Prostate
 Diet & Exercise
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

FDA Tells Patients to Stick With Diabetes Drug Linked to Cancer

There's no conclusive evidence that Lantus causes malignancy, agency says


Related Encyclopedia
 border=
Addison's Disease
Adenocarcinoma of the Lung and Brain Metastases
Basal Cell Carcinoma
Bladder Cancer
More...

Related Healthscout Videos
 border=
Optimistic Healing
Cancer Treatment for Any Size
Fever Kills Cancer
Saving Money on Healthcare
More...

Related Animations
 border=
Breast Self-Exam Video
Colon Cancer
Diabetes
More...

Related Drug Information
 border=
Actonel
Actos
Amaryl
Avandamet
More...

Related News Articles
 border=
Hormone Therapy & Breast Cancer
Study: High Breast Density Increases Risk for Cancer Recurrence
Pap Smear Alternative no Improvement
Risky Breast Cancer Drug OK'd by Canadian Cardiologists
More...

WEDNESDAY, July 1 (HealthDay News) -- Despite recent studies suggesting that the injected diabetes drug Lantus (insulin glargine) might boost cancer risk, the U.S. Food and Drug Administration on Wednesday urged patients who are on the medication to continue using it.

Three of four studies published last Friday in Diabetologia showed a potential link between Lantus -- an insulin analogue made by French drug company Sanofi-aventis -- and increased risks for various tumor types.

Text Continues Below



But, "the duration of patient follow-up in all four studies was shorter than what is generally considered necessary to evaluate for cancer risk from drug exposure," the FDA said in its first comment on the issue. "Further, inconsistencies in findings within and across individual studies raise concerns as to whether an association between the use of insulin glargine and cancer truly exists."

The agency also believes that differences in the various types of patients selected for each study may have swayed the results.

"Based on the currently available data, the FDA recommends that patients should not stop taking their insulin therapy without consulting a physician, since uncontrolled blood sugar levels can have both immediate and long-term serious adverse effects," the agency wrote.

A statement released Friday by the American Diabetes Association echoed the FDA's position. "For patients using glargine and considering switching to another form of insulin, the data in these studies make it unclear as to whether any one type of insulin increases the risk of cancer more than other types of insulin," the ADA said. "Patients concerned about these studies or their insulin regimen should talk to their doctor and should not stop taking their insulin on the basis of the findings reported here."

Lantus is an "analogue," or artificial version, of insulin and is used by both type 1 and type 2 diabetics to help control blood sugar over an extended period of time. It is given by injection once daily.

Page:  1 | 2 | Next >>

-- E.J. Mundell

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 7/1/2009

Related Links
 border=
From Healthscout's partner site on breast cancer, MyBreastCancerNetwork.com
VIDEO: Chemo booster cuts treatment time by two months
SYMPTOMS: Learn what to look for and what the symptoms mean
PROGNOSIS: Early detection and new treatments improve survival rates





SOURCES: July 1, 2009, statement, U.S. Food and Drug Administration; June 26, 2009, statement, American Diabetes Association; Wall Street Journal


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service    
Advertising Policy